The Global Beta-Lactam and Beta-lactamase Inhibitor Market was valued at USD 27.49 billion in 2019 and is predicted to reach USD 34.20 billion by 2030 with a CAGR of 1.9% during the forecast period.
Beta-lactam inhibitors are a class of antibiotic agents that have a beta lactam ring in their molecular structure. These antibiotic agents help fight against bacterial infections and protozoa infections by killing the bacteria directly or stopping it from growing. Some examples of Beta lactam inhibitors are penicillin, carbapenem etc. Beta-lactamase inhibitors are a class of drugs that block the activity of the Beta-lactam enzymes and restricts the degradation of Beta-lactam.
Access Full Description of this report at:-
Top Companies: Abbott Laboratories, Allergan plc. F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc., Merck & Co. Inc. Mylan N.V., Novartis International AG, Pfizer Inc., Sanofi and others.
The Beta-Lactam and Beta-lactamase Inhibitor market is segmented on the basis of drug class, disease, route of administration and geography. Based drug class, the market is segmented into penicillin, cephalosporin, carbapenem, monobactam and combination. Combination id sub segmented into Penicillin/Beta Lactamase Inhibitors, cephalosporins/Beta Lactamase Inhibitors and carbapenems/Beta Lactamase Inhibitors. Based on disease, the market is segmented into urinary tract infection (Excluding cUTI), respiratory infection, skin infection, complicated urinary tract infection (cUTI), nosocomial pneumonia, blood stream infection and other diseases. Nosocomial pneumonia is sub segmented into hospital acquired pneumonia, ventilator associated pneumonia and other nosocomial pneumonia. Based on route of administration, the market is segmented into oral, intravenous and other routes of administration. In terms of geographical analysis, the market is categorized into North America, Europe, Asia Pacific and RoW.
Request sample copy of this report at:-
North America is the leading region in the global Beta-Lactam and Beta-lactamase Inhibitor market. However, Asia Pacific region is anticipated to grow rapidly in terms of market size during the forecast period. The competitive nature of the global beta-lactam and beta-lactamase inhibitor market allows big players such as Mylan N.V., Allergan Plc., Abbott Laboratories etc to make large investments and further propel the growth of the market. The development and approval of new and effective beta-lactam and beta-lactamase inhibitor combinations by market players are expected to help the market thrive in future. For instance, in 2019, Indian drug manufacturer, Cipla has acquired rights to a novel and patented anti-infective called Elores. In the same year, imipenem-cilastatin-relebactam was also approved by the FDA for treating cUTIs and cIAIs.
About Next Move Strategy Consulting:
Next Move Strategy Consulting is an independent and trusted third-platform market intelligence provider, committed to deliver high quality, market research reports that help multinational companies to triumph over their competitions and increase industry footprint by capturing greater market share. Our research model is a unique collaboration of primary research, secondary research, data mining and data analytics.
We have been servicing over 1000 customers globally that includes 90% of the Fortune 500 companies over a decade. Our analysts are constantly tracking various high growth markets and identifying hidden opportunities in each sector or the industry. We provide one of the industry’s best quality syndicate as well as custom research reports across 10 different industry verticals. We are committed to deliver high quality research solutions in accordance to your business needs. Our industry standard delivery solution that ranges from the pre consultation to after-sales services, provide an excellent client experience and ensure right strategic decision making for businesses.
For more insights, please visit, https://www.nextmsc.com